| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Outline of Final Research Achievements |
We have discovered cancer-specific mRNA re-splicing that occurs on mature spliced mRNA and generates aberrant transcripts/proteins. The control of the re-splicing could be promoted by unknown activator upregulated and/or repressor downregulated in cancer cells.
Recent striking findings represent a breakthrough in the study of mRNA re-splicing. (1) TSG101 delta protein, generated via re-splicing of TSG101, enhances TSG101-stimulated cell proliferation and tumor growth. (2) mRNA re-splicing is repressed by the expression of TP53 often induced by cellular stress, (3) We have identified a repressor candidate of mRNA re-splicing by screening of siRNA library (156 kinds of RNA-binding proteins). Since the identified repressor is a known tumor suppressor, we postulate that global prevention of aberrant mRNA re-splicing, maintaining fidelity of splicing, is critical for the consequent tumor suppression. To prove this hypothesis is underway.
|
